Life Sciences Intellectual Property Lawyers | McDermott Will & Schulte

McDermott Will & Schulte, a global law firm

Life Sciences Intellectual

Property & Innovation

Decorative graphic
Overview

The McDermott Will & Schulte attorneys truly understand the science of our patents, give us personalized attention, and respond quickly to our questions.
Chambers USA, Life Sciences

As a life sciences company, your intellectual property (IP) is your most valuable asset—it’s what propels your growth, drives your success and sets you apart from competitors. But it may also be your most vulnerable asset.

How you commercialize your innovation and gain compliance is crucial for the success of your business. As competitors constantly work to capture your share of the market, it is imperative that your IP is protected to maximize its value. Our business-first perspective makes us uniquely equipped to help our clients build formidable IP portfolios, maximize their value and enforce or defend them in litigation.

See More

Recommended for its “excellent track record in representing life sciences and hi-tech clients in contentious cases, such as defending infringement allegations and assisting with post-grant reviews.”

Chambers USA

“[The firm’s] agents and attorneys have strong technical backgrounds (many hold PhDs) and notable patent drafting, prosecution and litigation skills – a combination which is not easy to find.”

IAM Patent 1000

IP Update Blog

Exploring the Latest in Intellectual Property Law

Unified Patent Court Resource Center

Stay informed of the latest updates and strategic insights on the new patent court.

“Life sciences patent litigation is a trump card for McDermott Will & Schulte’s IP group.”

IAM Patent 1000

Results
  • Representing United Therapeutics in its patent infringement suit against Liquidia Technologies alleging Liquidia infringes patents related to UT’s Tyvaso (treprostinil) product, a prescription inhalation solution for pulmonary arterial hypertension.
  • Representing Astellas in multiple patent infringement cases regarding its Lexiscan® product, a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress, as well as cases involving Myrbetriq® and XOSPATA®.
  • Successfully represented Amgen in defeating efforts by Sanofi’s and Regeneron to declare Amgen’s patents, covering a new class of cholesterol lowering anti-PCSK9 antibodies, invalid in this closely watched competitor case; secured a sweeping jury verdict after a one-week jury trial.

See More

Insights
Events
News & Media
Key contacts

Douglas H. Carsten

Partner

San Diego

William Gaede

Partner

Silicon Valley, San Francisco

Intellectual Property

Patent Litigation

Patent Portfolio Strategy & Counseling

Trademark, Copyright, & Advertising Litigation

Trademark & Copyright Strategy & Counseling

Life Sciences FDA, Global Regulatory & Market Access

Life Sciences Transactions & Strategic Growth